The effect of modafinil on cognitive function in breast cancer survivors
Open Access
- 4 June 2009
- Vol. 115 (12), 2605-2616
- https://doi.org/10.1002/cncr.24287
Abstract
BACKGROUND: The authors conducted a randomized clinical trial examining the effects of modafinil in reducing persistent fatigue in patients after treatment for cancer and performed secondary analyses to assess the effect of modafinil on cognitive function. METHODS: Breast cancer patients who reported a score of ≥2 on the Brief Fatigue Inventory were enrolled in the study. In phase 1 (P1), patients received 200 mg modafinil open‐label once daily for 4 weeks. In phase 2 (P2), patients with a positive response after P1 were randomized either to an additional 4 weeks of modafinil or to placebo. Tests of memory and attention selected from the Cognitive Drug Research (CDR) computerized cognitive assessment were performed at baseline (before modafinil) and after completing phases 1 and 2. The paired differences for each test score were subjected to a Wilcoxon signed rank test. RESULTS: Of the 82 women who were enrolled, 76 completed P1, and 68 completed all assessments in the study. Modafinil had a significant effect on the Speed of Memory (P = .0073) and Quality of Episodic Memory (P < .0001) during P1 of the study. After randomization at Week 8, those patients who continued modafinil demonstrated significantly greater improvement in Speed of Memory (P = .029), Quality of Episodic Memory (P = .0151), and mean Continuity of Attention (P = .0101) relative to the group that was switched to placebo. CONCLUSIONS: The authors found that modafinil improved cognitive performance in breast cancer survivors by enhancing some memory and attention skills. Although confirmation is needed, these findings suggest that modafinil may enhance quality of life in this patient population. Cancer 2009. © 2009 American Cancer Society.Keywords
This publication has 54 references indexed in Scilit:
- Persistent Neurocognitive Problems After Adjuvant Chemotherapy for Breast CancerClinical Breast Cancer, 2008
- Neuroendocrine-Immune Mechanisms of Behavioral Comorbidities in Patients With CancerJournal of Clinical Oncology, 2008
- Behavioral Symptoms in Patients With Breast Cancer and SurvivorsJournal of Clinical Oncology, 2008
- A randomised, placebo-controlled, double-blind trial of the effects of d-methylphenidate on fatigue and cognitive dysfunction in women undergoing adjuvant chemotherapy for breast cancerSupportive Care in Cancer, 2007
- Self-Reported Cognitive Impairment in Patients With CancerJournal of Oncology Practice, 2007
- AbstractsSupportive Care in Cancer, 2006
- Long-term efficacy and safety of modafinil (PROVIGIL®) for the treatment of excessive daytime sleepiness associated with narcolepsySleep Medicine, 2000
- A randomized trial of the long-term, continued efficacy and safety of modafinil in narcolepsySleep Medicine, 2000
- Self‐monitoring cognitive performance during sleep deprivation: effects of modafinil, d‐amphetamine and placeboJournal of Sleep Research, 1997
- The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessmentsEuropean Journal of Cancer, 1996